- Home
- CRIS vs XAIR Comparison
CRIS vs XAIR Comparison
Compare CRIS & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | XAIR |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 10.1M |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRIS | XAIR |
|---|---|---|
| Price | $0.83 | $0.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | $10.00 |
| AVG Volume (30 Days) | 113.4K | ★ 183.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,898,000.00 | $3,705,000.00 |
| Revenue This Year | $6.13 | $122.00 |
| Revenue Next Year | $7.86 | $58.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 31.50 | ★ 219.67 |
| 52 Week Low | $0.77 | $0.15 |
| 52 Week High | $3.13 | $3.78 |
Technical Indicators
Market Signals| Indicator | CRIS | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 34.19 |
| Support Level | $0.80 | $0.76 |
| Resistance Level | $1.04 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.03 | 11.28 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.